http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 16:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jun+02/26591377.html si-local-file:///var/storage/secattach/20260602/26591377.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jun+02/26591377.html Tue, 02 Jun 2026 16:00:00 -0400 INMB O.39467908 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jun+02/26591377.html si-local-file:///var/storage/secattach/20260602/26591377.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jun+02/26591377.html Tue, 02 Jun 2026 16:00:00 -0400 INMB O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+reports+positive+MRI+results+in+Alzheimer%27s+trial/26587797.html <p>INmune Bio Inc. (NASDAQ: INMB) announced results from MRI imaging analyses of its Phase 2 MINDFuL clinical trial testing XPro1595 in patients with early Alzheimer's disease. The company reported a statistically significant treatment effect on white matter biomarkers.</p> <p>In the full modified intent-to-treat population of 200 patients, XPro1595 showed a statistically significant difference in myelin compared to placebo after 24 weeks of treatment (p=0.0028) with a Cohen's d effect size of 0.46. The treatment effect strengthened in a subgroup of 100 patients with elevated inflammatory biomarkers, showing a Cohen's d of 0.59 (p=0.0098).</p> <p>The analysis used chi-separation MRI, a technique designed to http://www.streetinsider.com/FDA/INmune+Bio+reports+positive+MRI+results+in+Alzheimer%27s+trial/26587797.html Tue, 02 Jun 2026 08:01:05 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+reports+positive+MRI+results+in+Alzheimer%27s+trial/26587797.html <p>INmune Bio Inc. (NASDAQ: INMB) announced results from MRI imaging analyses of its Phase 2 MINDFuL clinical trial testing XPro1595 in patients with early Alzheimer's disease. The company reported a statistically significant treatment effect on white matter biomarkers.</p> <p>In the full modified intent-to-treat population of 200 patients, XPro1595 showed a statistically significant difference in myelin compared to placebo after 24 weeks of treatment (p=0.0028) with a Cohen's d effect size of 0.46. The treatment effect strengthened in a subgroup of 100 patients with elevated inflammatory biomarkers, showing a Cohen's d of 0.59 (p=0.0098).</p> <p>The analysis used chi-separation MRI, a technique designed to http://www.streetinsider.com/FDA/INmune+Bio+reports+positive+MRI+results+in+Alzheimer%27s+trial/26587797.html Tue, 02 Jun 2026 08:01:05 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+reports+positive+MRI+results+in+Alzheimer%27s+trial/26587797.html <p>INmune Bio Inc. (NASDAQ: INMB) announced results from MRI imaging analyses of its Phase 2 MINDFuL clinical trial testing XPro1595 in patients with early Alzheimer's disease. The company reported a statistically significant treatment effect on white matter biomarkers.</p> <p>In the full modified intent-to-treat population of 200 patients, XPro1595 showed a statistically significant difference in myelin compared to placebo after 24 weeks of treatment (p=0.0028) with a Cohen's d effect size of 0.46. The treatment effect strengthened in a subgroup of 100 patients with elevated inflammatory biomarkers, showing a Cohen's d of 0.59 (p=0.0098).</p> <p>The analysis used chi-separation MRI, a technique designed to http://www.streetinsider.com/FDA/INmune+Bio+reports+positive+MRI+results+in+Alzheimer%27s+trial/26587797.html Tue, 02 Jun 2026 08:01:05 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+reports+positive+MRI+results+in+Alzheimer%27s+trial/26587797.html <p>INmune Bio Inc. (NASDAQ: INMB) announced results from MRI imaging analyses of its Phase 2 MINDFuL clinical trial testing XPro1595 in patients with early Alzheimer's disease. The company reported a statistically significant treatment effect on white matter biomarkers.</p> <p>In the full modified intent-to-treat population of 200 patients, XPro1595 showed a statistically significant difference in myelin compared to placebo after 24 weeks of treatment (p=0.0028) with a Cohen's d effect size of 0.46. The treatment effect strengthened in a subgroup of 100 patients with elevated inflammatory biomarkers, showing a Cohen's d of 0.59 (p=0.0098).</p> <p>The analysis used chi-separation MRI, a technique designed to http://www.streetinsider.com/FDA/INmune+Bio+reports+positive+MRI+results+in+Alzheimer%27s+trial/26587797.html Tue, 02 Jun 2026 08:01:05 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+reports+positive+MRI+results+in+Alzheimer%27s+trial/26587729.html <p>INmune Bio Inc. (NASDAQ: INMB) announced results from MRI imaging analyses of its Phase 2 MINDFuL clinical trial testing XPro1595 in patients with early Alzheimer's disease. The company reported statistically significant treatment effects on white matter biomarkers.</p> <p>In the full modified intent-to-treat population of 200 patients, XPro1595-treated participants showed a statistically significant difference in myelin compared to placebo after 24 weeks of treatment (p=0.0028) with a Cohen's d effect size of 0.46. The treatment effect strengthened in a biomarker-enriched subgroup of 100 patients with amyloid-positivity and elevated inflammatory markers, achieving a Cohen's d of 0.59 (p=0.0098).</p> <p>The blinded analysis was performed by http://www.streetinsider.com/FDA/INmune+Bio+reports+positive+MRI+results+in+Alzheimer%27s+trial/26587729.html Tue, 02 Jun 2026 08:00:32 -0400 INMB http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%27s+Trial/26587601.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%27s+Trial/26587601.html Tue, 02 Jun 2026 08:00:00 -0400 INMB INMB http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%27s+Trial/26587601.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%27s+Trial/26587601.html Tue, 02 Jun 2026 08:00:00 -0400 INMB INMB http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%27s+Trial/26587601.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%27s+Trial/26587601.html Tue, 02 Jun 2026 08:00:00 -0400 INMB INMB http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%27s+Trial/26587601.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%27s+Trial/26587601.html Tue, 02 Jun 2026 08:00:00 -0400 INMB INMB http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html Tue, 02 Jun 2026 08:00:00 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html Tue, 02 Jun 2026 08:00:00 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html Tue, 02 Jun 2026 08:00:00 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Press+Releases/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html Tue, 02 Jun 2026 08:00:00 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html Tue, 02 Jun 2026 08:00:00 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html Tue, 02 Jun 2026 08:00:00 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html Tue, 02 Jun 2026 08:00:00 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html <p align="center"><i>XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.</i></p> <p align="center"><i>Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program.</i></p> <p align="justify"><strong>BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- </strong> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Reports+Statistically+Significant+Treatment+Effect+on+Advanced+White+Matter+MRI+Biomarker+in+Phase+2+MINDFuL+Alzheimer%26apos%3Bs+Trial/26587717.html Tue, 02 Jun 2026 08:00:00 -0400 A.50207248 INMB O.00386324 O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+publishes+phase+2+alzheimer%27s+trial+results+in+peer+journal/26499718.html <p>INmune Bio Inc. (NASDAQ: INMB) announced that results from its Phase 2 MINDFuL trial evaluating XPro1595 in Alzheimer's disease patients have been published in the peer-reviewed journal NPJ Dementia. The study examined the drug's safety and efficacy in patients with mild Alzheimer's disease characterized by inflammation biomarkers.</p> <p>The trial focused on a pre-specified subgroup of 100 patients with amyloid-beta positivity and two or more inflammation biomarkers including hsCRP, ESR, HbA1c, or APOE ε4 allele. According to the published results, XPro showed consistent trends across cognitive, functional, behavioral, and biomarker endpoints over 24 weeks. The study reported effect sizes up to 0.27 http://www.streetinsider.com/FDA/INmune+Bio+publishes+phase+2+alzheimer%27s+trial+results+in+peer+journal/26499718.html Fri, 15 May 2026 08:00:31 -0400 A.06822034 INMB O.20026344 O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+publishes+phase+2+alzheimer%27s+trial+results+in+peer+journal/26499718.html <p>INmune Bio Inc. (NASDAQ: INMB) announced that results from its Phase 2 MINDFuL trial evaluating XPro1595 in Alzheimer's disease patients have been published in the peer-reviewed journal NPJ Dementia. The study examined the drug's safety and efficacy in patients with mild Alzheimer's disease characterized by inflammation biomarkers.</p> <p>The trial focused on a pre-specified subgroup of 100 patients with amyloid-beta positivity and two or more inflammation biomarkers including hsCRP, ESR, HbA1c, or APOE ε4 allele. According to the published results, XPro showed consistent trends across cognitive, functional, behavioral, and biomarker endpoints over 24 weeks. The study reported effect sizes up to 0.27 http://www.streetinsider.com/FDA/INmune+Bio+publishes+phase+2+alzheimer%27s+trial+results+in+peer+journal/26499718.html Fri, 15 May 2026 08:00:31 -0400 A.06822034 INMB O.20026344 O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+publishes+phase+2+alzheimer%27s+trial+results+in+peer+journal/26499718.html <p>INmune Bio Inc. (NASDAQ: INMB) announced that results from its Phase 2 MINDFuL trial evaluating XPro1595 in Alzheimer's disease patients have been published in the peer-reviewed journal NPJ Dementia. The study examined the drug's safety and efficacy in patients with mild Alzheimer's disease characterized by inflammation biomarkers.</p> <p>The trial focused on a pre-specified subgroup of 100 patients with amyloid-beta positivity and two or more inflammation biomarkers including hsCRP, ESR, HbA1c, or APOE ε4 allele. According to the published results, XPro showed consistent trends across cognitive, functional, behavioral, and biomarker endpoints over 24 weeks. The study reported effect sizes up to 0.27 http://www.streetinsider.com/FDA/INmune+Bio+publishes+phase+2+alzheimer%27s+trial+results+in+peer+journal/26499718.html Fri, 15 May 2026 08:00:31 -0400 A.06822034 INMB O.20026344 O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+publishes+phase+2+alzheimer%27s+trial+results+in+peer+journal/26499718.html <p>INmune Bio Inc. (NASDAQ: INMB) announced that results from its Phase 2 MINDFuL trial evaluating XPro1595 in Alzheimer's disease patients have been published in the peer-reviewed journal NPJ Dementia. The study examined the drug's safety and efficacy in patients with mild Alzheimer's disease characterized by inflammation biomarkers.</p> <p>The trial focused on a pre-specified subgroup of 100 patients with amyloid-beta positivity and two or more inflammation biomarkers including hsCRP, ESR, HbA1c, or APOE ε4 allele. According to the published results, XPro showed consistent trends across cognitive, functional, behavioral, and biomarker endpoints over 24 weeks. The study reported effect sizes up to 0.27 http://www.streetinsider.com/FDA/INmune+Bio+publishes+phase+2+alzheimer%27s+trial+results+in+peer+journal/26499718.html Fri, 15 May 2026 08:00:31 -0400 A.06822034 INMB O.20026344 O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+publishes+Phase+2+Alzheimer%27s+trial+results+in+peer-reviewed+journal/26499719.html <p>INmune Bio Inc. (NASDAQ: INMB) announced that results from its Phase 2 MINDFuL trial in Alzheimer's disease have been published in NPJ Dementia, a peer-reviewed journal. The study evaluated XPro1595 (pegipanermin) in patients with mild Alzheimer's disease characterized by biomarkers of inflammation.</p> <p>The trial examined a pre-specified subgroup of 100 patients with amyloid-beta positivity and two or more inflammation biomarkers. In this enriched population, XPro showed directional improvements across cognitive, global, functional, behavioral, and biomarker endpoints over 24 weeks. No amyloid-related imaging abnormalities were observed during the study period.</p> <p>The published paper reports effect sizes up to 0.27 across various endpoints including http://www.streetinsider.com/FDA/INmune+Bio+publishes+Phase+2+Alzheimer%27s+trial+results+in+peer-reviewed+journal/26499719.html Fri, 15 May 2026 08:00:31 -0400 A.06822034 INMB O.20026344 O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+publishes+Phase+2+Alzheimer%27s+trial+results+in+peer-reviewed+journal/26499719.html <p>INmune Bio Inc. (NASDAQ: INMB) announced that results from its Phase 2 MINDFuL trial in Alzheimer's disease have been published in NPJ Dementia, a peer-reviewed journal. The study evaluated XPro1595 (pegipanermin) in patients with mild Alzheimer's disease characterized by biomarkers of inflammation.</p> <p>The trial examined a pre-specified subgroup of 100 patients with amyloid-beta positivity and two or more inflammation biomarkers. In this enriched population, XPro showed directional improvements across cognitive, global, functional, behavioral, and biomarker endpoints over 24 weeks. No amyloid-related imaging abnormalities were observed during the study period.</p> <p>The published paper reports effect sizes up to 0.27 across various endpoints including http://www.streetinsider.com/FDA/INmune+Bio+publishes+Phase+2+Alzheimer%27s+trial+results+in+peer-reviewed+journal/26499719.html Fri, 15 May 2026 08:00:31 -0400 A.06822034 INMB O.20026344 O.39467908